TrialClinical cancer research : an official journal of the American Association for Cancer Research2013

A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.

Andrew X Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.